In a report issued on August 6, Ryan Zimmerman from BTIG reiterated a Buy rating on Vericel Corp (VCEL), with a price target of $24. The company’s shares opened today at $18.15.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 21.5% and a 64.6% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vericel Corp with a $24 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.01 and a one-year low of $10.30. Currently, Vericel Corp has an average volume of 529.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio includes MACI and Epicel.